News | April 30, 2023
Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
Specialty Chemicals grew 38% YoY for FY23
Specialty Chemicals grew 38% YoY for FY23
The company is addressing these observations
The inspection concluded with no observations
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
Subscribe To Our Newsletter & Stay Updated
